GPB Passport icon GPB Passport icon Passport
GPB donate icon GPB donate icon Donate
Sign Up For Our Newsletter

News Articles: Aduhelm

The Food and Drug Administration has fully approved Leqembi, the first drug shown to slow down Alzheimer's disease.

Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

|
By:
  • Jon Hamilton
This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer's-affected brain. An experimental drug modestly slowed the brain disease's progression, researchers reported Tuesday.

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

|
By:
  • Jon Hamilton
Amyloid plaques are characteristic features of Alzheimer's disease. The new drug Aduhelm is able to remove this sticky substance that builds up in the brains of patients with the disease, but many doctors are still skeptical of how well it really works.

Cost and controversy are limiting use of new Alzheimer's drug

A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.

|
By:
  • Jon Hamilton
As part of a clinical study, a patient with Alzheimer's disease receives an infusion of aducanumab at a Providence, R.I., hospital in 2019. Aducanumab is being marketed as Aduhelm.

A New Alzheimer's Drug Comes With Lots Of Questions About How To Use It

Weeks after the Food and Drug Administration approved the Alzheimer's drug Aduhelm, doctors are struggling to figure out who should get the drug and how to use it safely.

|
By:
  • Jon Hamilton